Our partners and especially our health services face unprecedented challenges over the next few months. The research response to COVID-19 is second only in importance to the clinical care challenges posed by the epidemic. The MACH has responded by helping our health services and research institutes lead the fight-back by supporting highest priority COVID-19 research. 

​

Please contact us with any COVID-19 queries at MACH-COVIDtrials@unimelb.edu.au

​

​

MACH COVID-19 Activities

The Committee meet regularly to deploy its wide-ranging expertise to make a consensus recommendation as to which interventional clinical trials are of the highest priority to support MACH-affiliated health services.

​

​

Current recommendations are found below with information updated after each Committee meeting:

Factors favouring an assessment as a highest priority trial may include:

​

• Funding from the NHMRC/MRFF

• An adaptive design

• An opportunity to join an outstanding quality international study

• Studies that nest in biobankable or diagnostic material

• Studies addressing a particular local need

​

MACH invites partner Research Offices to alert us to studies that are sufficiently advanced to be seeking ethics and governance approval and other queries related to COVID-19 research and trials (including non-clinical trials). 

​

Streamlining ethical approval across MACH

Research Managers (through the statewide Hospital Research Managers Committee) have agreed to fast-track COVID-19 trials through Human Research Ethics Committee (HREC) approval and are reviewing the use of the framework of National Mutual Acceptance (NMA).

Recent News & Media

COVID-19 Resources